News for Apellis Pharmaceuticals, Inc. (APLS)

Apellis Pharmaceuticals Inc (APLS), a global biopharmaceutical company known for pioneering complement medicine, announced on February 24, 2025, that it will pr

WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. ( APLS) today announced that the company will present at the TD Cowen 45th Ann

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc.

**media[545163]**

On February 7, 2025, Deep Track Capital, LP (Trades, Portfolio) executed a strategic acquisition of 2,515,513 shares in Ikena Oncology Inc. The transaction was

On December 31, 2024, BRAIDWELL LP (Trades, Portfolio) executed a significant transaction involving the acquisition of shares in DBV Technologies SA. The firm a

EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, recently expanded its holdings in Eton Pharmaceuticals Inc by acquiring an additional 583,3

EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, recently made a strategic decision to reduce its holdings in Atea Pharmaceuticals Inc (AVIR

EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, recently executed a significant transaction involving Aadi Bioscience Inc. On December 31,

On December 31, 2024, Deep Track Capital, LP (Trades, Portfolio) made a strategic move by acquiring 523,989 shares of OnKure Therapeutics Inc at a price of $8.6

On December 31, 2024, Deep Track Capital, LP (Trades, Portfolio) made a significant move by acquiring an additional 1,949,942 shares of enGene Holdings Inc (ENG

On December 31, 2024, Deep Track Capital, LP (Trades, Portfolio) executed a significant transaction involving SpringWorks Therapeutics Inc (SWTX). The firm redu

On December 31, 2024, Deep Track Capital, LP (Trades, Portfolio) executed a significant transaction involving Nektar Therapeutics (NKTR), reducing its holdings

On December 31, 2024, Deep Track Capital, LP (Trades, Portfolio) executed a significant transaction involving the reduction of its holdings in Nurix Therapeutic

On December 31, 2024, Deep Track Capital, LP (Trades, Portfolio) executed a significant transaction involving 4D Molecular Therapeutics Inc (FDMT), reducing its

**media[540746]**

On January 31, 2025, Deep Track Capital, LP (Trades, Portfolio) made a strategic move by acquiring 3,023,484 shares of Maze Therapeutics Inc. This transaction w